MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
The Pharma Data
JANUARY 10, 2021
For more information, please contact: SOURCE: MorphoSys AG via EQS Newswire. View source version on accesswire.com: [link].
Clinical Supply Events Licensing Regulations 
52 
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer
The Pharma Data
JANUARY 24, 2021
In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases. PharmaDrug Inc.
Let's personalize your content